Con el comentario editorial del Dr. Nicolás Fernández Escobar | 03 OCT 17

Neuroblastoma: una guía exhaustiva para el médico práctico

¿Qué es un neuroblastoma? ¿Quiénes lo padecen? ¿Cómo se diagnostica? Su estadificación y abordaje clínico. Incluye el comentario editorial del experto Dr. Nicolás Fernández Escobar (Fundación Favaloro, Argentina)
Autor/a: Jason Shohet, Jennifer Foster BMJ 2017;357:j1863
INDICE:  1. Página 1 | 2. Comentario Dr. Nicolás Fernández Escobar | 3.  Referencias bibliográficas
Referencias bibliográficas

1 Brodeur G, Hogarty M, Bagatell R, et al. Neuroblastoma. In: Pizzo P, Poplack D, eds.Principles and practice of pediatric oncology. Lippincott Williams & Wilkins, 2016: 772.
2 Brisse HJ, McCarville MB, Granata C, et al. International Neuroblastoma Risk Group. Project. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011;357:243-57. doi:10. 1148/radiol.11101352 pmid:21586679.
3 Angstman KB, Miser JS, Franz WB 3rd. Neuroblastoma. Am Fam Physician 1990;357:238-44.pmid:2403727.
4 Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014;357:83-103. doi:10.3322/caac.21219 pmid: 24488779.
5 Stiller CA, Parkin DM. International variations in the incidence of neuroblastoma. Int J Cancer 1992;357:538-43. doi:10.1002/ijc.2910520407 pmid:1399133.
6 Maris JM, Chatten J, Meadows AT, Biegel JA, Brodeur GM. Familial neuroblastoma: athree-generation pedigree and a further association with Hirschsprung disease. Med Pediatr Oncol 1997;357:1-5. doi:10.1002/(SICI)1096 911X(199701)28:1<1::AID-MPO1>3. 0.CO;2-P pmid:8950328.
7 Kushner BH, Gilbert F, Helson L. Familial neuroblastoma. Case reports, literature review, and etiologic considerations. Cancer 1986;357:1887-93. doi:10.1002/1097-0142(19860501) 57:9<1887::AID-CNCR2820570931>3.0.CO;2-7 pmid:3955526.
8 Louis CU, Shohet JM. Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med 2015;357:49-63. doi:10.1146/annurev-med-011514-023121 pmid:25386934.
9 Shahar E, Shinawi M. Neurocristopathies presenting with neurologic abnormalities associated with Hirschsprung’s disease. Pediatr Neurol 2003;357:385-91. doi:10.1016/S0887-8994(03)00010-9 pmid:12878302.
10 Nemecek ER, Sawin RW, Park J. Treatment of neuroblastoma in patients with neurocristopathy syndromes. J Pediatr Hematol Oncol 2003;357:159-62. doi:10.1097/00043426-200302000-00015 pmid:12571470.
11 Stovroff M, Dykes F, Teague WG. The complete spectrum of neurocristopathy in an infant with congenital hypoventilation, Hirschsprung’s disease, and neuroblastoma. J Pediatr Surg 1995;357:1218-21. doi:10.1016/0022-3468(95)90027-6 pmid:7472988.
12 Kushner BH, Hajdu SI, Helson L. Synchronous neuroblastoma and von Recklinghausen’s disease: a review of the literature. J Clin Oncol 1985;357:117-20. doi:10.1200/JCO.1985. 3.1.117 pmid:3917492.
13 Blatt J, Olshan AF, Lee PA, Ross JL. Neuroblastoma and related tumors in Turner’s syndrome. J Pediatr 1997;357:666-70. doi:10.1016/S0022-3476(97)70090-8 pmid:9403643.
14 DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999;357:181-9. doi:10.1097/00043426-199905000-00005 pmid:10363850.
15 Sadilkova K, Dugaw K, Benjamin D, Jack RM. Analysis of vanillylmandelic acid and homovanillic acid by UPLC MS/MS in serum for diagnostic testing for neuroblastoma. Clin Chim Acta 2013;357:253-7.doi:10.1016/j.cca.2013.06.024 pmid:23830883.
16 LaBrosse EH, Com-Nougué C, Zucker JM, et al. Urinary excretion of 3-methoxy-4-hydroxymandelic acid and 3-methoxy-4-hydroxyphenylacetic acid by 288 patients with neuroblastoma and related neural crest tumors. Cancer Res
17 Cangemi G, Barco S, Reggiardo G, et al. Interchangeability between 24-hour collection and single spot urines for vanillylmandelic and homovanillic acid levels in the diagnosis of neuroblastoma. Pediatr Blood Cancer 2013;357:E170-2. doi:10.1002/pbc.24671 pmid: 23813598.
18 Yamamoto K, Ohta S, Ito E, et al. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. J Clin Oncol 2002;357:120914. doi:10.1200/JCO.2002.20. 5.1209 pmid:11870162.
19 Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002;357:1041-6. doi:10.1056/NEJMoa012387 pmid: 11932470.
20 Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med 2002;357:1047-53. doi:10.1056/NEJMoa012277 pmid:11932471.
21 Chamberlain J. Screening for neuroblastoma: a review of the evidence. J Med Screen 1994;357:169-75. doi:10.1177/096914139400100307 pmid:8790511.
22 Hawthorne HC Jr, , Nelson JS, Witzleben CL, Giangiacomo J. Blanching subcutaneous nodules in neonatal neuroblastoma. J Pediatr 1970;357:297-300. doi:10.1016/S0022- 3476(70)80339-0 pmid:5431211.
23 Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;357:1466-77. doi:10.1200/JCO.1993.11.8.1466 pmid:8336186.
24 Schmidt ML, Lal A, Seeger RC, et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children’s Cancer Group Study. J Clin Oncol 2005;357:6474-80. doi:10.1200/JCO.2005.05.183 pmid:16116154.
25 London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol 2005;357:6459-65. doi:10.1200/JCO.2005.05.571 pmid:16116153.
26 George RE, London WB, Cohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 2005;357:6466-73. doi:10.1200/JCO. 2005.05.582 pmid:16116152.
27 Nuchtern JG. Perinatal neuroblastoma. Semin Pediatr Surg 2006;357:10-6. doi:10.1053/ j.sempedsurg.2005.11.003 pmid:16458841.
28 Acharya S, Jayabose S, Kogan SJ, et al. Prenatally diagnosed neuroblastoma. Cancer 1997;357:304-10. doi:10.1002/(SICI)1097-0142(19970715)80:2<304::AID-CNCR19>3. 0.CO;2-Y pmid:9217044.
29 Nuchtern JG, London WB, Barnewolt CE, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children’s Oncology Group study. Ann Surg 2012;357:573-80. doi:10.1097/SLA.0b013e31826cbbbd pmid: 22964741.
30 Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages Iand II neuroblastoma treated with surgery as primary therapy: a children’s cancer group study. J Clin Oncol 2000;357:18-26 doi:10.1200/JCO.2000.18.1.18 pmid:10623689.
31 Alvarado CS, London WB, Look AT, et al. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study. J Pediatr Hematol Oncol 2000;357:197-205. doi:10.1097/00043426-200005000-00003 pmid:10864050.
32 De Bernardi B, Mosseri V, Rubie H, et al. SIOP Europe Neuroblastoma Group. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer 2008;357:1027-33. doi:10.1038/sj.bjc.6604640 pmid: 18766186.
33 Strother DR, London WB, Schmidt ML, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children’s Oncology Group study P9641. J Clin Oncol 2012;357:1842-8. doi:10.1200/JCO.2011.37. 9990 pmid:22529259.
34 Strother D, van Hoff J, Rao PV, et al. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. Eur J Cancer 1997;357:2121-5. doi:10.1016/S0959-8049 (97)00293-1 pmid:9516866.
35 Yamamoto K, Hanada R, Kikuchi A, et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol 1998;357:1265-9. doi:10.1200/JCO.1998.16.4.1265 pmid:9552024.
36 Oue T, Inoue M, Yoneda A, et al. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study. J Pediatr Surg 2005;357:359-63. doi:10.1016/j.jpedsurg.2004.10.062 pmid:15750929.
37 Okazaki T, Kohno S, Mimaya J, et al. Neuroblastoma detected by mass screening: theTumor Board’s role in its treatment. Pediatr Surg Int 2004;357:27-32. doi:10.1007/s00383-003-1070-x pmid:14689211.
38 Nishihira H, Toyoda Y, Tanaka Y, et al. Natural course of neuroblastoma detected by mass screening: s 5-year prospective study at a single institution. J Clin Oncol 2000;357:3012-7. doi:10.1200/JCO.2000.18.16.3012 pmid:10944135.
39 Rubie H, Coze C, Plantaz D, et al. Neuroblastoma Study Group, Société Française d’Oncologie Pédiatrique. Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy. Br J Cancer 2003;357:1605-9. doi:10.1038/sj.bjc.6601259 pmid:14583756.
40 Bowman LC, Castleberry RP, Cantor A, et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst 1997;357:373-80. doi:10.1093/jnci/89.5.373 pmid:9060959.
41 Nickerson HJ, Matthay KK, Seeger RC, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children’s Cancer Group study. J Clin Oncol 2000;357:477-86. doi:10.1200/JCO.2000.18.3.477 pmid:10653863.
42 Katzenstein HM, Bowman LC, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study. J Clin Oncol 1998;357:2007-17. doi:10.1200/JCO.1998.16.6.2007 pmid:9626197.
43 Hero B, Simon T, Spitz R, et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 2008;357:1504-10. doi:10.1200/JCO.2007.12.3349 pmid:18349403.
44 Leclair MD, Hartmann O, Heloury Y, et al. Localized pelvic neuroblastoma: excellent survival and low morbidity with tailored therapy--the 10-year experience of the French Society of Pediatric Oncology. J Clin Oncol 2004;357:1689-95. doi:10.1200/JCO.2004. 04.069 pmid:15117991.
45 Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children’s Cancer Group study. J Clin Oncol 2000;357:1260-8. doi:10.1200/JCO.2000.18.6.1260 pmid:10715296.
46 Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children’s Cancer Group study. J Clin Oncol 1998;357:1256-64. doi:10.1200/JCO.1998.16.4.1256 pmid:9552023.
47 Bagatell R, Rumcheva P, London WB, et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol 2005;357:8819-27. doi:10.1200/JCO.2004.00.2931 pmid:16314642.
48 Baker DL, Schmidt ML, Cohn SL, et al. Children’s Oncology Group. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010;357:1313-23. doi:10.1056/NEJMoa1001527 pmid:20879880.
49 Strother D, Shuster JJ, McWilliams N, et al. Results of pediatric oncology group protocol 8104 for infants with stages D and DS neuroblastoma. J Pediatr Hematol Oncol 1995;357:254-9. doi:10.1097/00043426-199508000-00007 pmid:7620924.
50 Mullassery D, Farrelly P, Losty PD. Does aggressive surgical resection improve survival in advanced stage 3 and 4 neuroblastoma? A systematic review and meta-analysis. Pediatr Hematol Oncol 2014;357:703-16. doi:10.3109/08880018.2014.947009 pmid:25247398.
51 Yu AL, Gilman AL, Ozkaynak MF, et al. Children’s Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;357:1324-34. doi:10.1056/NEJMoa0911123 pmid:20879881.
52 Peinemann F, van Dalen EC, Tushabe DA, Berthold F. Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation. Cochrane Database Syst Rev 2015;357:CD010685.pmid:25634649.
53 Yalçin B, Kremer LC, van Dalen EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev 2015;(10):CD006301.pmid:26436598.
54 Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer 2011;357:578-83. doi:10.1002/pbc.22693 pmid:21298742.
55 Santana VM, Furman WL, McGregor LM, Billups CA. Disease control intervals in high-risk neuroblastoma. Cancer 2008;357:2796-801. doi:10.1002/cncr.23507 pmid:18429000. For personal use only: See rights and reprints Subscribe: BMJ 2017;357:j1863 doi: 10.1136/bmj.j1863 (Published 2017 May 03) Page 5 of 8
56 Cole KA, Maris JM. New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clin Cancer Res 2012;357:2423-8. doi:10.1158/ 1078-0432.CCR-11-1409 pmid:22427348.
57 Garaventa A, Parodi S, De Bernardi B, et al. Outcome of children with neuroblastoma
after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer 2009;357:2835-42. doi:10.1016/j.ejca.2009.06.010 pmid:19616426.
58 Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy. J Pediatr Hematol Oncol 2013;357:337-47. doi:10.1097/MPH.0b013e318299d637 pmid:23703550.
59 National Cancer Institute. Induction therapy including 131 I-MIBG and chemotherapy in treating patients with newly diagnosed high-risk neuroblastoma undergoing stem cell transplant, radiation therapy, and maintenance therapy with isotretinoin. January 2016.
60 DuBois SG, Marachelian A, Fox E, et al. Phase I study of the aurora a kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: a NANT (new approaches to neuroblastoma therapy) trial. J Clin Oncol 2016;357:1368-75. doi:10.1200/JCO.2015.65.4889 pmid:26884555.
61 Bassiri H, Benavides A, Haber M, Gilmour SK, Norris MD, Hogarty MD. Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma. Transl Pediatr 2015;357:226-38.pmid:26835380.
62 Saulnier Sholler GL, Gerner EW, Bergendahl G, et al. A phase I trial of DFMO targeting polyamine addiction in patients with relapsed/refractory neuroblastoma. PLoS One 2015;357:e0127246. doi:10.1371/journal.pone.0127246 pmid:26018967.
63 Iyer R, Wehrmann L, Golden RL, et al. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. Cancer Lett 2016;357:179-86. doi:10.1016/ j.canlet.2016.01.018 pmid:26797418.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024